CR20110064A - Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéutico - Google Patents
Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéuticoInfo
- Publication number
- CR20110064A CR20110064A CR20110064A CR20110064A CR20110064A CR 20110064 A CR20110064 A CR 20110064A CR 20110064 A CR20110064 A CR 20110064A CR 20110064 A CR20110064 A CR 20110064A CR 20110064 A CR20110064 A CR 20110064A
- Authority
- CR
- Costa Rica
- Prior art keywords
- benzodiazepina
- piridina
- daa
- binding
- image diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos nuevos adecuados para marcar o ya marcados con F, con métodos para preparar tales compuestos, con composiciones que comprenden dichos compuestos, con conjuntos de elementos que comprenden dichos compuestos o composiciones y con los usos de dichos compuestos, composiciones o conjuntos de elementos en terapias y para diagnósticos por imágenes mediante tomografia de emisión de positrones (PET).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161903 | 2008-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110064A true CR20110064A (es) | 2011-03-30 |
Family
ID=41198601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110064A CR20110064A (es) | 2008-08-06 | 2011-02-04 | Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéutico |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110200535A1 (es) |
EP (1) | EP2321279B1 (es) |
JP (1) | JP2011529929A (es) |
KR (1) | KR20110041559A (es) |
CN (1) | CN102112448B (es) |
AR (1) | AR073263A1 (es) |
AU (1) | AU2009278279B2 (es) |
BR (1) | BRPI0917099A2 (es) |
CA (1) | CA2733105A1 (es) |
CL (1) | CL2011000237A1 (es) |
CO (1) | CO6351715A2 (es) |
CR (1) | CR20110064A (es) |
DO (1) | DOP2011000046A (es) |
EA (1) | EA018650B1 (es) |
EC (1) | ECSP11010808A (es) |
IL (1) | IL210597A0 (es) |
MX (1) | MX2011001406A (es) |
NZ (1) | NZ590923A (es) |
PE (1) | PE20110226A1 (es) |
SV (1) | SV2011003830A (es) |
TW (1) | TW201010734A (es) |
UY (1) | UY32037A (es) |
WO (2) | WO2010015340A1 (es) |
ZA (1) | ZA201101700B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007339954B2 (en) | 2006-12-26 | 2013-06-20 | Lantheus Medical Imaging, Inc. | Ligands for imaging cardiac innervation |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
GB0904715D0 (en) | 2009-03-19 | 2009-05-06 | Ge Healthcare Ltd | Aryloxyanilide derivataives |
WO2011110488A1 (en) * | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | A novel pet imaging agent of amyloid plaques and its precursor |
BR122020018186B1 (pt) | 2010-05-11 | 2021-07-27 | Lantheus Medical Imaging, Inc | Uso de agentes de imagiologia para preparação de uma composição para detecção do transportador de norepinefrina (net) e método para a detecção de net |
CN104311562B (zh) | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
SG2014013767A (en) | 2011-09-09 | 2014-05-29 | Lantheus Medical Imaging Inc | Compositions, methods, and systems for the synthesis and use of imaging agents |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
JP6637884B2 (ja) | 2013-11-08 | 2020-01-29 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ブロモドメインおよびエクストラターミナル(bet)タンパク質インヒビターを使用するがんのための併用療法 |
EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
MX2016011160A (es) | 2014-02-28 | 2017-04-27 | Tensha Therapeutics Inc | Tratamiento de afecciones asociadas con la hiperinsulinemia. |
KR20170032473A (ko) | 2014-08-08 | 2017-03-22 | 다나-파버 캔서 인스티튜트 인크. | 디아제판 유도체 및 그의 용도 |
MX2017001757A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
SG11201703414VA (en) | 2014-10-27 | 2017-05-30 | Tensha Therapeutics Inc | Bromodomain inhibitors |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
MX2018003031A (es) | 2015-09-11 | 2018-08-01 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas. |
JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
RU2742035C2 (ru) | 2015-11-25 | 2021-02-01 | Дана-Фарбер Кэнсер Инститьют, Инк. | Бивалентные ингибиторы бромодоменов и пути их применения |
CN105541931B (zh) * | 2016-01-07 | 2018-08-17 | 江西师范大学 | 一种氟代糖苷衍生物及其制备方法 |
JP7341139B2 (ja) * | 2017-12-01 | 2023-09-08 | ユーシービー バイオファルマ エスアールエル | イメージング剤 |
CN111039853B (zh) * | 2019-12-26 | 2023-02-14 | 安徽大学 | 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006353A1 (fr) * | 1997-08-04 | 1999-02-11 | Taisho Pharmaceutical Co., Ltd. | Derives aryloxyaniline |
JP2000001476A (ja) * | 1998-06-15 | 2000-01-07 | Taisho Pharmaceut Co Ltd | アリールオキシ含窒素アリールアミン誘導体 |
US6870069B2 (en) * | 2003-01-10 | 2005-03-22 | National Institute Of Radiological Sciences | Phenyloxyaniline derivatives |
JP2004231647A (ja) * | 2003-01-10 | 2004-08-19 | Natl Inst Of Radiological Sciences | フェニルオキシアニリン誘導体 |
GB0329716D0 (en) * | 2003-12-23 | 2004-01-28 | Amersham Plc | Radical trap |
GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
US8644910B2 (en) * | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
DE102005055524B4 (de) * | 2005-11-22 | 2013-02-07 | BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG | Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers |
US20080293969A1 (en) * | 2005-11-22 | 2008-11-27 | Ge Healthcare Limited | 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors |
GB0525949D0 (en) * | 2005-12-21 | 2006-02-01 | Hammersmith Imanet Ltd | Pet radiotracers |
MX2008016344A (es) * | 2006-06-21 | 2009-02-12 | Ge Healthcare Ltd | Productos radiofarmaceuticos. |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
-
2009
- 2009-07-25 WO PCT/EP2009/005399 patent/WO2010015340A1/en active Application Filing
- 2009-08-03 TW TW098126076A patent/TW201010734A/zh unknown
- 2009-08-05 WO PCT/EP2009/005651 patent/WO2010015387A1/en active Application Filing
- 2009-08-05 AU AU2009278279A patent/AU2009278279B2/en not_active Ceased
- 2009-08-05 EA EA201100301A patent/EA018650B1/ru not_active IP Right Cessation
- 2009-08-05 CA CA2733105A patent/CA2733105A1/en not_active Abandoned
- 2009-08-05 MX MX2011001406A patent/MX2011001406A/es not_active Application Discontinuation
- 2009-08-05 PE PE2011000123A patent/PE20110226A1/es not_active Application Discontinuation
- 2009-08-05 AR ARP090102997A patent/AR073263A1/es not_active Application Discontinuation
- 2009-08-05 BR BRPI0917099A patent/BRPI0917099A2/pt not_active IP Right Cessation
- 2009-08-05 EP EP09777654.6A patent/EP2321279B1/en not_active Not-in-force
- 2009-08-05 KR KR1020117005160A patent/KR20110041559A/ko not_active Application Discontinuation
- 2009-08-05 JP JP2011521474A patent/JP2011529929A/ja active Pending
- 2009-08-05 NZ NZ590923A patent/NZ590923A/xx not_active IP Right Cessation
- 2009-08-05 US US13/057,215 patent/US20110200535A1/en not_active Abandoned
- 2009-08-05 UY UY0001032037A patent/UY32037A/es not_active Application Discontinuation
- 2009-08-05 CN CN200980130507.6A patent/CN102112448B/zh not_active Expired - Fee Related
-
2011
- 2011-01-12 IL IL210597A patent/IL210597A0/en unknown
- 2011-02-04 CL CL2011000237A patent/CL2011000237A1/es unknown
- 2011-02-04 SV SV2011003830A patent/SV2011003830A/es not_active Application Discontinuation
- 2011-02-04 DO DO2011000046A patent/DOP2011000046A/es unknown
- 2011-02-04 CR CR20110064A patent/CR20110064A/es unknown
- 2011-02-04 EC EC2011010808A patent/ECSP11010808A/es unknown
- 2011-02-04 CO CO11013225A patent/CO6351715A2/es not_active Application Discontinuation
- 2011-03-04 ZA ZA2011/01700A patent/ZA201101700B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2011000046A (es) | 2011-02-28 |
EP2321279B1 (en) | 2014-07-02 |
WO2010015340A1 (en) | 2010-02-11 |
AR073263A1 (es) | 2010-10-28 |
EP2321279A1 (en) | 2011-05-18 |
EA201100301A1 (ru) | 2011-12-30 |
IL210597A0 (en) | 2011-03-31 |
JP2011529929A (ja) | 2011-12-15 |
AU2009278279B2 (en) | 2014-04-17 |
ZA201101700B (en) | 2014-08-27 |
WO2010015387A1 (en) | 2010-02-11 |
UY32037A (es) | 2010-03-26 |
ECSP11010808A (es) | 2011-03-31 |
MX2011001406A (es) | 2011-03-21 |
PE20110226A1 (es) | 2011-04-01 |
US20110200535A1 (en) | 2011-08-18 |
BRPI0917099A2 (pt) | 2016-02-16 |
NZ590923A (en) | 2012-12-21 |
CN102112448B (zh) | 2014-08-06 |
TW201010734A (en) | 2010-03-16 |
CN102112448A (zh) | 2011-06-29 |
CO6351715A2 (es) | 2011-12-20 |
CL2011000237A1 (es) | 2011-07-29 |
CA2733105A1 (en) | 2010-02-11 |
EA018650B1 (ru) | 2013-09-30 |
AU2009278279A1 (en) | 2010-02-11 |
KR20110041559A (ko) | 2011-04-21 |
SV2011003830A (es) | 2011-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110064A (es) | Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéutico | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
CL2014000225A1 (es) | Compuestos derivados de 1,2,4-triazol; composicion farmaceutica; procedimiento de preparacion de procursores de los mismos y el uso como moduladores del transporte nuclear en el tratamiento de enfermedades tales como cancer. | |
CL2011002255A1 (es) | Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras. | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
SV2011003954A (es) | Agonistas del receptor gpr120 y usos de los mismos | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
UY33029A (es) | Antagonistas de espiro-oxindol de mdm2 | |
CO6551740A2 (es) | Derivados pirazólicos como moduladores de los canales de calcio activados por la liberación de calcio | |
BRPI0821805A2 (pt) | Sistema para limitar a dose de radiação para um paciente durante uma varredura por tomografia computadorizada, métodos para reduzir a dose de radiação para um indivíduo e para varrer um volume de interesse, e, sistema para controlar a radiação durante uma varredura por tomografia computadorizada. | |
ECSP13012368A (es) | Composiciones farmacéuticas de co-cristales de tramadol y coxibs | |
CL2014000210A1 (es) | Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. | |
UY30595A1 (es) | Métodos de marcacion con fluor radioactivo | |
MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
WO2016040458A3 (en) | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging | |
UY32523A (es) | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides | |
CL2011002907A1 (es) | Compuestos derivados de nitrilo; sus composiciones farmacéuticas y su uso para el tratamiento de enfermedades hiperproliferativas. | |
CR20150638A (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos | |
AU2010332841A8 (en) | Prostate specific membrane antigen inhibitors | |
CL2012002823A1 (es) | Composición farmacéutica para el tratamiento de la diabetes y los trastornos relacionados, que comprende un sensibilizador de insulina seleccionado entre pioglitazona y rosiglitazona, glimepirida y metmorfina; formulación farmacéutica oral que la comprende; kit para tratar diabetes tipo ii; y uso de dicha formulación para tratar diabetes. | |
CL2015000890A1 (es) | Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras. | |
MX340487B (es) | Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central. |